B. parapertussis as the cause of cough illnesses suspected of being pertussis in California and other selected areas of the United States, we have examined the results of studies performed at Focus Diagnostics in California. Specifically, we have analyzed the IS481 and IS1001 positivity of nasopharyngeal samples submitted for PCR during the 3-year period 2008-2010.
METHODS
Nucleic acids were extracted from 200 lL of upper respiratory specimens (nasopharyngeal swab in viral transport media; nasopharyngeal aspirate) on the MagNA Pure LC Instrument (Roche Diagnostics) with a Total Nucleic Acid Isolation Kit. An elution volume of 50 lL was used for the extracted nucleic acids. Two real-time PCR protocols were used to identify specimens containing B. pertussis and B. parapertussis. Both protocols amplified and detected sequences in IS481 and IS1001.
The first protocol was used to test specimens prior to October 2010 and was performed on the ABI Prism 7900HT instrument (Applied Biosystems). Primers were designed to amplify a 151-bp region of IS481 and a 213-bp region of IS1001. Dual-labeled probes were used to detect the products of amplification. Each reaction also contained TaqMan Exogenous Internal Positive Control Reagents (Applied Biosystems) to detect PCR inhibition. Real-time PCR results with cycle threshold (C T ) values ,38 were considered to be positive for the appropriate target (IS481 or IS1001). Specimens with C T values .38 but ,50 were repeated to confirm the presence of IS481 or IS1001.
The second protocol was implemented beginning October 2010. In this method, IS481 and IS1001 targets were amplified and detected with B. pertussis Primer Mix and B. parapertussis Primer Mix (Focus Diagnostics) on the 3M Integrated Cycler (Focus Diagnostics). In the second protocol, real-time PCR results with cycle threshold (C T ) values ,35 were considered to be positive for the appropriate target (IS481 or IS1001). Specimens with C T values .35 but ,40 were repeated to confirm the presence of IS481 or IS1001. Method comparison studies showed 100% correlation between the 2 protocols.
RESULTS
During the 3-year period 2008-2010, the majority of specimens were submitted from 9 states (California, Florida, Illinois, Michigan, New Jersey, Ohio, Texas, Virginia, and Washington); our analyses will involve only data from these states. Sixty-three percent of the samples were from children ,10 years of age and 22% were from adults $20 years of age. Sixty-nine percent of specimens were from California. Of the total specimens submitted, 9.5% were positive for either IS481 or IS1001.
Of all the positive samples, 13.9% were IS1001 positive. The 9-state overall IS1001 positivity rates by year were 16.5% in 2010, 7.9% in 2009, and 8.9% in 2008. The IS1001 positivity rates by age group were as follows: ,5 years, 66%; 5-10 years, 28.7%; 11-20 years, 3.8%; and $21 years, 0.4%. In contrast, the IS481 positivity rates for the same age groups were 38.5%, 28.3%, 22.3%, and 10.9%, respectively. There were 17 dualpositive samples (positive for both IS481 and IS1001) during the 3-year period, and 12 of them (70.6%) occurred in 2010.
The weekly submission of specimens for PCR study for the 3-year observation period is presented in Figure 1 
DISCUSSION
B. pertussis and B. parapertussis have limited genetic diversity; nevertheless, the antibody generated against B. pertussis proteins that offers protection against B. pertussis offers little protection against B. parapertussis infection [1, [7] [8] [9] [10] . Another notable difference between the 2 subspecies is that B. pertussis secretes pertussis toxin and B. parapertussis does not. B. parapertussis infections can cause unrecognized infection, mild pertussis, or classic pertussis [1, [14] [15] [16] [17] . In general, pertussis due to B. parapertussis is generally milder and of shorter duration. However, classic pertussis with paroxysmal cough, whooping, and posttussive vomiting occurs.
In the prevaccine era, study findings suggested that B. parapertussis illnesses were much less common than B. pertussis illnesses [1] . Similar to those for B. pertussis, the epidemic cycles occurred at 3-4 year intervals. In conjunction with the pertussis vaccine efficacy trials in the 1990s, B. parapertussis illnesses were noted in Italy, Germany, and Sweden [8, 9, [14] [15] [16] [17] . In 6 of the efficacy trials, B. parapertussis accounted for between 2.1% and 25% of the culture-positive cases. In contrast with the observations in Europe, documented B. parapertussis illnesses in the United States during the last 35 years have been uncommon [1] .
Because of its increased sensitivity, the routine use of PCR in the diagnosis of pertussis has contributed to the finding of more cases of pertussis in recent years [1, 4, 13, 18] . B. pertussis contains 238 copies of IS481 and no copies of IS1001, whereas B. parapertussis has 22 copies of IS1001 and no copies of IS481 [19] . The multiple copies of IS481 are responsible for the high sensitivity of PCR, which uses this primer in the diagnosis of pertussis. However, this high level of sensitivity is associated with an increased risk of falsepositive results [1, 11-13, 18, 20, 21] . False-positive diagnoses of pertussis caused by B. pertussis can be the result of DNA contamination in the clinic due to recent vaccine use or previous patients with pertussis [21] . False-positive identification of IS481 may have occurred in this study, but we have no way to address this possibility. However, false-positive identification of IS1001 seems unlikely, because IS1001 it is not present in vaccines and its copy numbers are low.
Bordetella holmesii also may contain IS481 (8-10 copies) and IS1001 (unknown number of copies) so that if PCR assay is positive for both, this organism is thought to be the causative agent [18, 20] . However, dual positivity could also be the result of concomitant infection with both B. pertussis and B. parapertussis [8, 22, 23] . Because no cultures were performed, the cause of illness associated with our 17 dual-positive specimens is not known.
Recent experiences as well as the present study suggest that B. parapertussis infections are common but have been generally overlooked [24] . In this study we have shown that B. pertussis illness peaks in the summer, whereas B. parapertussis was endemically prevalent throughout the first 2½ years of the study. During the last 6 months of 2010, B. parapertussis infections became more prevalent and accounted for a much greater percentage of the positive samples. Our findings also suggest that the age spectrum of B. parapertussis illness is different from that of B. pertussis illness. Only 4.2% of the IS1001-positive specimens occurred in persons .10 years of age, compared with 32.2% for IS481-positive specimens. Our data indicate that B. parapertussis infections contribute significantly to the overall pertussis burden and contribute to the pool of children thought to have vaccine failure. This was particularly notable in the summer, fall, and early winter of 2010. 
